AAN 2021 | COVID-19 & MS at AAN 2021
Afagh Garjani
• 26 Apr 2021
Afagh Garjani, MD, Nottingham University Hospitals NHS Trust, Nottingham, UK, discusses the updates on COVID-19 in patients with multiple sclerosis (MS) presented at AAN 2021. In particular, Dr Garjani highlights discussions on the potential increased risk of severe infection associated with the use of anti-CD20 disease-modifying therapies and how this has led to treatment delays for many patients. Data was presented looking into the impact of treatment delays on MS disease activity. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.
Disclosures
Dr Garjani reports the following disclosures:
Research support: UK MS Society
Speaker honorarium: MS Academy
Travel support: Novartis
